Orgenesis Inc. ORGS
We take great care to ensure that the data presented and summarized in this overview for Orgenesis Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ORGS
Top Purchases
Top Sells
About ORGS
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
Insider Transactions at ORGS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 24
2024
|
Jacob Safier > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,000
-0.32%
|
$0
$0.58 P/Share
|
|
Jun 24
2024
|
Jacob Safier > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.32%
|
$0
$0.58 P/Share
|
|
Apr 16
2024
|
Jacob Safier > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,000
-0.32%
|
$0
$0.5 P/Share
|
|
Apr 16
2024
|
Jacob Safier > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.32%
|
$0
$0.51 P/Share
|
|
Apr 10
2024
|
Jacob Safier > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,000
-0.32%
|
$0
$0.54 P/Share
|
|
Apr 10
2024
|
Jacob Safier > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.32%
|
$0
$0.59 P/Share
|
|
Apr 01
2024
|
Victor Miller CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+50.0%
|
$0
$0.5 P/Share
|
|
Feb 01
2024
|
Jacob Safier > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,100
+0.32%
|
$0
$0.33 P/Share
|
|
Jan 31
2024
|
Jacob Safier > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
5,000
+0.16%
|
$0
$0.35 P/Share
|
|
Jan 30
2024
|
Jacob Safier > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.8%
|
$0
$0.33 P/Share
|
|
Jan 26
2024
|
Jacob Safier > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.81%
|
$0
$0.32 P/Share
|
|
Jan 25
2024
|
Jacob Safier > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.81%
|
$0
$0.32 P/Share
|
|
Jan 22
2024
|
Jacob Safier > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.33%
|
$0
$0.29 P/Share
|
|
Jan 18
2024
|
Jacob Safier > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.33%
|
$0
$0.33 P/Share
|
|
Jan 11
2024
|
Jacob Safier > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,000
+0.07%
|
$0
$0.33 P/Share
|
|
Jan 10
2024
|
Jacob Safier > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.33%
|
$0
$0.37 P/Share
|
|
Dec 21
2023
|
Jacob Safier > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.33%
|
$0
$0.45 P/Share
|
|
Dec 12
2023
|
Jacob Safier > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
3,000
+0.1%
|
$0
$0.54 P/Share
|
|
Dec 11
2023
|
Jacob Safier > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,000
+0.07%
|
$0
$0.53 P/Share
|
|
Dec 01
2023
|
Jacob Safier > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,016
+0.03%
|
$0
$0.46 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 25K shares |
|---|---|
| Open market or private purchase | 162K shares |
| Open market or private sale | 30K shares |
|---|